retatrutide phase 3 trials Today, we shared new data from two of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Eli Lilly infiltrates anti-obesity market

Mounjaro is a completely different medication

Group yoga

If the active compound can penetrate the skin's outer barrier (the stratum corneum) and reach the dermis and subcutaneous tissue, it enters systemic circulation through dermal capillaries without going through your GI tract or liver

Utilising our expertise and experience in medication adherence and patient compliance we acquire, monitor, analyse, guide and interpret data to deliver absolute clarity and bring confidence to sponsors, trialists, and ultimately, patients

In Mar26, BMS Sotyktu (Deucravacitinib) wins FDA approval to treat adults with active psoriatic arthritis (PsA) Total Revenue: $48.67B Founded Year: 1923 Total Employees: 69,200 Headquarters: Bagsvaerd, Denmark Market Cap: $127.23B Stock Exchange: CPH Novo Nordisk is a global healthcare company focused on diabetes, obesity, and rare diseases, with a strong leadership position in metabolic disorders driven by its GLP-1based therapies and innovation-led pipeline

This is the same dual-agonist approach that made tirzepatide so effective, but retatrutide goes further